CompletedPhase 1NCT00003368

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Studying Adult T-cell leukemia/lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Alan P. Venook, MD, MD
University of California, San Francisco
Intervention
irinotecan hydrochloride(drug)
Eligibility
18 years · All sexes
Timeline
1998 – 2006

Study locations (30)

Collaborators

Alliance for Clinical Trials in Oncology

Published results

No published results indexed yet.Verified against PubMed's DataBankList cross-reference. This means either: (a) the trial has not yet published, (b) results were published without registering the NCT cross-reference, or (c) our index is still catching up. Patients can check ClinicalTrials.gov directly or search PubMed for the PI's recent work.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00003368 on ClinicalTrials.gov

Other trials for Adult T-cell leukemia/lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Adult T-cell leukemia/lymphoma →

← Back to all trials